2. Guangshengtang is a rapidly developing manufacturer of nucleoside anti-HBV drugs. At present, the company is the only manufacturer with three first-line anti-HBV drugs, with an operating income of 254 million yuan in 20 14, a year-on-year increase of 43%. Among them, Entecavir's revenue and gross profit accounted for 47.3% and 48.6% respectively, which was the main driving product of the company's performance. The company Entecavir was listed on February 3, 20/kloc-0. In 20 12-20 14, the sales proportion of Entecavir increased from 17.2% to 47.3%, and the gross profit proportion increased from 17.4% to 48.6%.